Updated co-financing, eligibility and transition thresholds, and more from Gavi

Home > Updated co-financing, eligibility and transition thresholds, and more from Gavi

Gavi has released updates to their co-financing, eligibility, and transition thresholds in accordance with the latest data from World Bank, as well as updated vaccine funding guidelines.

Eligibility

Countries are eligible for Gavi support if their Gross National Income (GNI) per capita has been less than or equal to US$1,730.

Countries with a GNI per capita equal to or below US$1,085 are categorized as “initial self-financing.” During this phase, countries contribute US$0.20 per dose (no annual increase).

When a country’s reported three-year average GNI per capita and its most recent GNI per capita is above the US$1,730 threshold, countries will enter the accelerated transition phase. In line with the December 2022 Gavi Board decision, a country in accelerated transition can apply for new vaccine support during the full eight years of their accelerated transition, while continuing to co-finance in line with Gavi policy.

Current transition phase status and vaccine eligibility by country can be found on page 26 and 27 of the Application Process Guidelines which also contain more detailed information on Gavi’s co-financing, eligibility, and transition policy. Access the Gavi Application Process Guidelines below.

 

Vaccine funding guidelines

The guidelines provide information and resources for countries to optimize their vaccine portfolio, assess alternative vaccine options, and submit vaccine switch requests. Details regarding prices for the malaria vaccine have been included, along with expectations for country co-financing obligations.

The guidelines also reflect recent changes to eligibility for the MR vaccine introductions. To be eligible, countries must meet the following criterion: Routine MCV1 coverage, as determined by WUENIC, must be ≥80% OR coverage of the most recent nationwide measles preventive campaign must be ≥80%, as determined by a high-quality coverage survey using WHO’s latest methodology. The previous requirement to have a WHO/UNICEF (WUENIC) DTP3 coverage estimate of ≥70% is no longer required for MR vaccine introductions. Access the Gavi Vaccine Funding Guidelines below.

 

Further information can be found on the Gavi website.

Submit your work

Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.